Introduction: The extent of complete pathological response (pCR) has become the surrogate measure for favorable long-term results in neoadjuvant chemotherapy (NCT) trials. The objective of this study was to describe the incidence of CRP obtained with NCT in breast cancer patients treated at 3 institutions in Bogotá, Colombia. Materials and methods: A cross-sectional study in which patients with breast cancer treated with NCT were included in 3 institutions in Bogotá between 2013 and 2017. A descriptive analysis of the data extracted from the medical records of the patients was carried out to characterize the population and a bivariate analysis with the purpose of comparing clinical variables between the group with and without pCR. Results: 314 patients who received NCT and surgical management were included. Most of the patients had B HER 2 negative luminal tumors (n = 93, 29.6%). The general rate of pCR was 33.4% (n = 105). The tumors with the highest rate of pCR were HER 2 tumors (55%, n = 11) followed by TN tumors (50.8%, n = 31) and HER2 positive luminal B tumors (42.4%, n = 36) . Conclusions: Patients undergoing neoadjuvant chemotherapy and those who had HER 2 positive breast tumors had a higher rate of complete pathological response compared to patients with other types of positive receptors in their tumors. Studies with a larger sample are needed to confirm these findings.
February 25, 2021 7:21 PM
Analysis of clinical outcomes according to treatment with QTN in breast cancer